

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter 1, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Nordion (Canada), Inc.</p> <p>2. 447 March Road Ottawa, Ontario, CN K2K 1X8</p>	<p>In accordance with letter dated</p> <p>May 10, 2016</p> <p>3. License number: 54-28275-02MD is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: March 31, 2025</p> <p>5. Docket No.: 030-30793 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Iodine-123</p> <p>B. Iodine-125</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. No Possession Authorized</p> <p>B. No Possession Authorized</p> <p>9. Authorized use</p> <p>A. In accordance with 10 CFR 32.72, the licensee is authorized to distribute the licensed material described in Items 6 and 7 of this license to persons licensed in accordance with 10 CFR 35.100, 35.200, 35.300, or under equivalent licenses of any Agreement State.</p> <p>B. In accordance with 10 CFR 32.72, the licensee is authorized to distribute the licensed material described in Items 6 and 7 of this license to persons licensed in accordance with 10 CFR 35.100, 35.200, 35.300, or under equivalent licenses of any Agreement State.</p>

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
54-28275-02MD

Docket or Reference Number  
030-30793

Amendment No. 13

6. Byproduct, source,  
and/or special nuclear  
material

C. Iodine-131

D. Yttrium-90

E. Cobalt-60

7. Chemical and/or physical form

C. Any

D. Microspheres (Nordion  
(Canada), Inc., Model  
Therasphere).

E. Sealed Sources  
(Nordion(Canada), Inc., Model  
C-375)

8. Maximum amount that licensee  
may possess at any one time  
under this license

C. No Possession  
Authorized

D. No Possession  
Authorized

E. No Possession  
Authorized

9. Authorized use

C. In accordance with 10 CFR 32.72, the licensee is authorized to distribute the licensed material described in Items 6 and 7 of this license to persons licensed in accordance with 10 CFR 35.100, 35.200, 35.300, or under equivalent licenses of any Agreement State.

D. In accordance with 10 CFR 32.74, the licensee is authorized to distribute the licensed material described in Items 6 and 7 of this license to persons licensed in accordance with 35.1000, or under equivalent licenses of any Agreement State.

E. In accordance with 10 CFR 32.74, the licensee is authorized to distribute the licensed material described in Items 6 and 7 of this license to persons licensed in accordance with 35.1000, or under equivalent licenses of any Agreement State.

**CONDITIONS**

10. The licensee may distribute material from 447 March Road, Ottawa, Ontario, Canada and 4004 Wesbrook Mall, Vancouver, British Columbia, Canada.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
54-28275-02MDDocket or Reference Number  
030-30793

Amendment No. 13

11. This license does not authorize possession or use of licensed material.
12. Notwithstanding 10 CFR 32.72 (a)(4)(ii) the licensee may label I-131 monoclonal antibody product in accordance with their letter dated November 24, 2005.
13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated September 23, 2014 [ML14279A523]  
B. Letter dated February 25, 2015 [ML15071A409]  
C. Letter dated March 18, 2015 [ML15086A153]  
D. Letter dated March 30, 2015 [ML15090A161]  
E. Letter dated May 19, 2015 [ML15159A919])

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 11, 2016By: Elizabeth Ullrich  
Region I